Corbus Pharmaceuticals (CRBP) News Today $8.34 +0.06 (+0.66%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period HC Wainwright Reiterates Buy Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)February 20 at 2:05 AM | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday.February 19 at 8:20 AM | marketbeat.comMizuho Securities Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)February 16, 2025 | markets.businessinsider.comCorbus Pharmaceuticals announces data from its US, UK study of CRB-701February 14, 2025 | markets.businessinsider.comCorbus Pharmaceuticals falls after trial data for lead assetFebruary 14, 2025 | msn.comRBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)February 14, 2025 | markets.businessinsider.comCRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025February 14, 2025 | globenewswire.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by AnalystsFebruary 14, 2025 | americanbankingnews.comBrokers Issue Forecasts for CRBP FY2029 EarningsFebruary 14, 2025 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)February 13, 2025 | markets.businessinsider.comEquities Analysts Set Expectations for CRBP FY2029 EarningsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst A.February 12, 2025 | marketbeat.comCorbus presents new cancer drug study at ASCO GUFebruary 12, 2025 | msn.comCRBP stock touches 52-week low at $9.1 amid market challengesFebruary 12, 2025 | msn.comCorbus Pharmaceuticals announces clinical data for CRB-701February 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GUFebruary 11, 2025 | globenewswire.comH.C. Wainwright maintains $75 target on Corbus stockFebruary 11, 2025 | msn.comCorbus Pharmaceuticals' (CRBP) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 target price (down previously from $80.00) on shares of Corbus Pharmaceuticals in a research note on Monday.February 10, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Receives a Buy from H.C. WainwrightFebruary 10, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by AnalystsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toFebruary 7, 2025 | marketbeat.comCRBP stock touches 52-week low at $9.26 amid market challengesFebruary 3, 2025 | msn.comPiper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)February 1, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 9.1% in JanuaryCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a decline of 9.1% from the December 31st total of 2,650,000 shares. Approximately 22.1% of the company's stock are sold short. Based on an average trading volume of 324,600 shares, the short-interest ratio is currently 7.4 days.February 1, 2025 | marketbeat.comCorbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 28, 2025 | globenewswire.comCRBP stock touches 52-week low at $10.43 amid market fluctuationsJanuary 24, 2025 | msn.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock, Insider Trading ActivityJanuary 21, 2025 | benzinga.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 9.1%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,410,000 shares, a drop of 9.1% from the December 15th total of 2,650,000 shares. Currently, 22.1% of the company's stock are short sold. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 7.4 days.January 18, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.comStockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a report on Monday.January 13, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buJanuary 13, 2025 | marketbeat.comCorbus Pharmaceuticals announes data for CRB-701 from Western Dose studyJanuary 8, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025January 8, 2025 | markets.businessinsider.comCorbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Sees Significant Growth in Short InterestCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,650,000 shares, an increase of 5.6% from the November 30th total of 2,510,000 shares. Currently, 24.3% of the shares of the company are short sold. Based on an average daily trading volume, of 448,900 shares, the days-to-cover ratio is currently 5.9 days.January 1, 2025 | marketbeat.comState Street Corp Buys 153,243 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)State Street Corp raised its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 34.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 595,576 shares of the biopharmaceutical company's stocDecember 26, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus recommendation of "Buy" from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strDecember 19, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gainsDecember 17, 2024 | marketwatch.comCharles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Charles Schwab Investment Management Inc. grew its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 224.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 93,643 shares of the biopharmaceutical company's stock afterDecember 17, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms marketDecember 14, 2024 | marketwatch.comPromising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic FocusDecember 12, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid TumorsDecember 9, 2024 | globenewswire.comWalleye Capital LLC Has $763,000 Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Walleye Capital LLC decreased its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 75.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,963 shares of the biopharmaceutical companyDecember 8, 2024 | marketbeat.comWhy Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comHighVista Strategies LLC Grows Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)HighVista Strategies LLC raised its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,292 shares of theDecember 3, 2024 | marketbeat.comFDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical CancerDecember 3, 2024 | globenewswire.comPiper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight RecommendationDecember 2, 2024 | msn.comCorbus, Viking initiated at overweight by Piper SandlerDecember 2, 2024 | msn.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Acuta Capital Partners LLCAcuta Capital Partners LLC decreased its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,500 shares of the biNovember 28, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In NowNovember 26, 2024 | insidermonkey.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Recommendation of "Buy" by BrokeragesShares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has isNovember 24, 2024 | marketbeat.comCorbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx ConferenceNovember 21, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 13.5% in OctoberCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,380,000 shares, a decline of 13.5% from the October 15th total of 2,750,000 shares. Approximately 20.2% of the shares of the company are short sold. Based on an average trading volume of 648,200 shares, the days-to-cover ratio is presently 3.7 days.November 16, 2024 | marketbeat.com Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Media Mentions By Week CRBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBP News Sentiment▼0.200.60▲Average Medical News Sentiment CRBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBP Articles This Week▼83▲CRBP Articles Average Week Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UPB News ATXS News AURA News PHAT News CMRX News ORKA News ATAI News RVNC News PRME News ESPR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBP) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts